{"id":249817,"date":"2025-08-11T00:00:00","date_gmt":"2025-08-11T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2024-biopharma-myelodysplastic-syndromes-landscape-forecast\/"},"modified":"2026-03-31T10:25:21","modified_gmt":"2026-03-31T10:25:21","slug":"nrlfon0008-2025-biopharma-myelodysplastic-syndromes-landscape-forecast-niche-rare-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2025-biopharma-myelodysplastic-syndromes-landscape-forecast-niche-rare-disease-landscape-forecast\/","title":{"rendered":"Myelodysplastic Syndromes &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Myelodysplastic syndromes (<abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (<abbr title=\"acute myeloid leukemia\">AML<\/abbr>). <abbr title=\"Bristol Myers Squibb\">BMS<\/abbr> \/ Acceleron\u2019s Reblozyl (luspatercept) for lower-risk adult <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>, Astex Pharmaceuticals\u2019 Inqovi (decitabine and cedazuridine) for higher-risk adult <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> and refractory <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>, Servier\u2019s Tibsovo (ivosidenib) for relapsed or refractory <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> with an <abbr title=\"isocitrate dehydrogenase 1\">IDH1<\/abbr> mutation, and Geron\u2019s Rytelo (imetelstat) for low- to intermediate-1-risk adult <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> are effective treatment options. Other pharmacological approaches to managing the disease (e.g., lenalidomide [<abbr title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Revlimid, generics]) are designed to ameliorate symptoms and extend patients\u2019 survival, although there is a significant gap in the treatment of refractory disease. The <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> pipeline is robust and promising, and several projected market entrants are poised to penetrate the lower-risk, intermediate-risk, and higher-risk subpopulations.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How have the U.S. launches of Reblozyl, Inqovi, Tibsovo, and Rytelo changed <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> treatment in that country? How will the treatment of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> in Europe change following the expected <abbr title=\"European Medicines Agency\">EMA<\/abbr> label expansions of Tibsovo and launch of Rytelo?<\/li>\n<li>What is the commercial outlook for current and emerging therapies for <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>?<\/li>\n<li>Which emerging therapies are most likely to have an impact on the <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> therapy market by 2034?<\/li>\n<li>How will the size of the <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> population change by 2034?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>Primary research:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Country-specific interviews with thought-leading hematologists \/ oncologists<\/li>\n<li>Survey data collected for this and other Clarivate research<\/li>\n<\/ul>\n<ul class=\"round-bullets\">\n<\/ul>\n<p><strong>Epidemiology:<\/strong> Diagnosed incident and diagnosed prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by country, diagnosed and drug-treated incident cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr>, diagnosed incident and prevalent cases of <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> by morphology, and diagnosed incident and prevalent cases by prognostic risk<\/p>\n<p><strong>Forecast: <\/strong>Drug-level sales and patient share of key <abbr title=\"myelodysplastic syndromes\">MDS<\/abbr> therapies in 2024 and 2034<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-249817","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-myelodysplastic-syndromes","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249817\/revisions"}],"predecessor-version":[{"id":575744,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249817\/revisions\/575744"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}